Clinical pharmacology of gatifloxacin, a new fluoroquinolone

Clinical Infectious Diseases

Volumn 31, Issue SUPPL. 2, 2000, Pages

  Grasela, D M ^a  

^a BRISTOL MYERS SQUIBB PHARMACEUTICAL RESEARCH INSTITUTE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CYTOCHROME P450; GATIFLOXACIN;

ANTIMICROBIAL ACTIVITY; BIOAVAILABILITY; CLINICAL TRIAL; CONFERENCE PAPER; CRYSTALLURIA; DRUG DISTRIBUTION; DRUG EXCRETION; DRUG FORMULATION; DRUG STRUCTURE; GLUCOSE TOLERANCE; HUMAN; META ANALYSIS; MINIMUM INHIBITORY CONCENTRATION; PHARMACODYNAMICS; PHOTOSENSITIVITY DISORDER; PRIORITY JOURNAL; QT INTERVAL; STREPTOCOCCUS PNEUMONIAE;

ADMINISTRATION, ORAL; ADULT; AGED; ANTI-INFECTIVE AGENTS; CATIONS; DRUG INTERACTIONS; DRUG TOLERANCE; FEMALE; FLUOROQUINOLONES; FOOD; HUMANS; INJECTIONS, INTRAVENOUS; MALE; SAFETY; THERAPEUTIC EQUIVALENCY; TISSUE DISTRIBUTION;

EID: 0034453448     PISSN: 10584838     EISSN: None     Source Type: Journal    
DOI: 10.1086/314061     Document Type: Conference Paper

References (48)

1. Haemophilus influenzae and Moraxella catarrhalis from patients with community-acquired respiratory tract infections: Antimicrobial susceptibility patterns from the SENTRY Antimicrobial Surveillance Program (United States and Canada, 1997)
2. In vitro activity of gatifloxacin, compared with ciprofloxacin, clarithromycin, erythromycin, and rifampin, against Legionella species
3. Anti-pneumococcal activity of gatifloxacin compared with other quinolone and non-quinolone agents
4. Survey of blood stream infections attributable to gram-positive cocci: Frequency of occurrence and antimicrobial susceptibility of isolates collected in 1997 in the United States, Canada, and Latin America from the SENTRY Antimicrobial Surveillance Program
5. Comparative antimicrobial activity of gatifloxacin tested against Streptococcus spp., including quality control guidelines and E-test method validation
6. In-vitro activities of gatifloxacin, sparfloxacin and trovafloxacin against 103 strains of Legionella spp.
7. Activities of new fluoroquinolones against fluoroquinolone-resistant pathogens of the lower respiratory tract
8. Activities of gatifloxacin compared to those of seven other agents against anaerobic organisms
9. Comparison of the antibacterial activities of the quinolones Bay 12-9039, gatifloxacin (AM 1155), trovafloxacin, clinafloxacin, levofloxacin and ciprofloxacin
10. In vitro antibacterial activity of AM-1155, a novel 6-fluoro-8-methoxy quinolone
11. Gatifloxacin
12. Treating acute, uncomplicated bacterial sinusitis with gatifloxacin
13. Gatifloxacin vs. clarithromycin in the management of acute sinusitis
14. Gatifloxacin vs. cefuroxime axetil in patients with acute exacerbations of chronic bronchitis
15. Gatifloxacin treatment in patients with acute exacerbations of chronic bronchitis: Clinical trial results
16. Treating community-acquired pneumonia with once-daily gatifloxacin vs. twice-daily clarithromycin
17. Treating community-acquired pneumonia with once-daily gatifloxacin vs. once-daily levofloxacin
18. Treating community-acquired pneumonia in hospitalized patients: Gatifloxacin vs. cetriaxone/clarithromycin
19. Safety and tolerability of gatifloxacin, an advanced-generation 8-methoxy fluoroquinolone
20. Fluoroquinolone toxicity profiles: A review focusing on newer agents
21. Expanded activity and utility of the new fluoroquinolones: A review
22. Pharmacokinetics of the R- and S-enantiomers of gatifloxacin (GTX), a new fluoroquinolone antibiotic, following single oral doses to healthy Caucasian volunteers
23. A dose-escalation study of the safety, tolerability, and pharmacokinetics of intravenous gatifloxacin in healthy adult men
24. Single- and multiple-dose pharmacokinetics of AM-1155, a new 6-fluoro-8-methoxy quinolone, in humans
25. Multiple-dose pharmacokinetics and excretion balance of gatifloxacin (GTX), a new fluoroquinolone antibiotic, following oral administration to healthy Caucasian volunteers
26. Interchangeability of 400-mg intravenous and oral gatifloxacin in healthy adults
27. Effect of a high-fat meal on the bioavailability of gatifloxacin in healthy volunteers
28. Safety, tolerance and food effect after single and multiple oral doses of gatifloxacin (GTX), a new fluoroquinolone antibiotic to healthy Caucasian volunteers
29. Pharmacokinetics (PK) and safety of gatifloxacin in combination with ferrous sulfate or calcium carbonate in healthy volunteers
30. Comparative tolerability of the newer fluoroquinolone antibacterials
31. Pharmacokinetics of gatifloxacin and interaction with an antacid containing aluminum and magnesium
32. Age and gender effects on the pharmacokinetics of gatifloxacin
33. Population pharmacokinetics (PPK) of gatifloxacin in adults with acute bacterial exacerbation of chronic bronchitis (ABECB)
34. Safety and pharmacokinetics of a single oral dose of gatifloxacin in patients with moderate to severe hepatic impairment
35. Pharmacokinetics of gatifloxacin (AM-1155) in patients with impaired renal function
36. Effect of multiple-dose gatifloxacin or ciprofloxacin on glucose homeostasis and insulin production in patients with noninsulin-dependent diabetes mellitus maintained with diet and exercise
37. Lack of effect of multiple dose gatifloxacin (GAT) on oral glucose tolerance (OGTT), glucose and insulin homeostasis, and glyburide pharmacokinetics (PK) in patients with type II non-insulin dependent diabetes mellitus (NIDDM)
38. Open-label, nonrandomized study of the effect of gatifloxacin on the pharmacokinetics of midazolam in healthy male volunteers
39. Structure-activity and structure-side-effect relationships for the quinolone antibacterials
40. Reduced phototoxicity of a fluoroquinolone antibacterial agent with a methoxy group at the 8 position in mice irradiated with long-wavelength UV light
41. Phototoxicity and photochemical generation of reactive oxygen by new quinolones
42. A double-blind, placebo- and positive-controlled randomized study to investigate the phototoxic potential of gatifloxacin, a new fluoroquinolone
43. The influence of gatifloxacin (AM-1155) on pharmacokinetics and metabolism of theophylline in rats and humans
44. Pharmacokinetics (PK) of concomitantly administered gatifloxacin and digoxin
45. Reduction of digoxin to 20R-dihydrodigoxin by cultures of Eubacterium lentum
46. Digoxin-inactivating bacteria: Identification in human gut flora
47. Inactivation of digoxin by Eubacterium lentum, an anaerobe of the human gut flora